Anti‐VEGF Therapy for Diabetic Eye Diseases. Issue 6 (November 2017)

• Record Type: Journal Article
• Authors: Bahrami, Bobak; Hong, Thomas; Gilles, Mark C.; Chang, Andrew
• Is Part Of: Asia-Pacific journal of ophthalmology. Volume 6:Issue 6(2017)
• Publication Date: 2017-11
• Subjects: diabetic retinopathy -- diabetic macular edema -- vascular endothelial growth factor; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; Periodicals; 617.7005
• DOI: 10.22608/APO.2017350
• Languages: English
• ISSNs: 0129-1653

Abstract

Abstract : Abstract: : Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the working‐age population. The identification of vascular endothelial growth factor (VEGF) as a key mediator in the pathogenesis of DR has revolutionized the management of this vision‐threatening disease. There is now strong evidence supporting intravitreal anti‐VEGF therapy as first line in the management of sight‐threatening diabetic macular edema (DME), along with a growing body of evidence to support the use of anti‐VEGF drugs for proliferative DR. This review summarizes the role of VEGF in DR, the evidence for anti‐VEGF therapy, safety considerations, and the future of anti‐VEGF therapy for the management of DR.